US2023064711A1PendingUtilityA1
Compositions, kits and methods for enhancing therapeutic compliance
Est. expiryDec 30, 2039(~13.4 yrs left)· nominal 20-yr term from priority
Inventors:Michael Belkin
A61K 47/40A61K 47/10A61K 31/27A61K 31/4178A61K 47/36A61K 9/5153A61K 45/06A61K 31/5575A61K 47/38A61K 9/127A61K 9/0048A61K 47/28A61K 31/4409A61K 9/1647A61K 31/137A61K 47/186A61K 31/439A61P 27/06A61K 9/08A61K 47/06A61K 47/183A61K 47/32A61K 47/34
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure encompasses pharmaceutical composition, kits and methods for enhancing therapeutic compliance.
Claims
exact text as granted — not AI-modified1 - 33 . (canceled)
34 . A pharmaceutical composition comprising:
(i) a prostaglandin analogue (PGA), or a pharmaceutically acceptable salt thereof, solvate thereof, hydrate thereof, any stereoisomer therefore, physiologically functional derivative thereof; and (ii) between about 0.1% w/w to about 3% w/w pilocarpine, or a pharmaceutically acceptable salt thereof, solvate thereof, hydrate thereof, stereoisomer thereof, or physiologically functional derivative thereof.
35 . The pharmaceutical composition of claim 34 , comprising between about 0.1% w/w to about 1% w/w pilocarpine, or a pharmaceutically acceptable salt thereof, solvate thereof, hydrate thereof, stereoisomer thereof, or physiologically functional derivative thereof.
36 . The pharmaceutical composition of claim 34 , wherein the PGA is latanoprost, or a pharmaceutically acceptable salt thereof, solvate thereof, hydrate thereof, any stereoisomer therefore, physiologically functional derivative thereof.
37 . The pharmaceutical composition of claim 36 , comprising from 0.005% w/w to 2% w/w latanoprost.
38 . The pharmaceutical composition of claim 34 , further comprising a carrier, excipient or additive.
39 . The pharmaceutical composition of claim 34 , wherein the pharmaceutical composition is an ophthalmic ointment.
40 . A method of reducing intra-ocular pressure in an individual in need thereof, the method comprising administering to the individual the pharmaceutical composition of claim 34 .
41 . A method of treating glaucoma in an individual in need thereof, the method comprising administering to the individual the pharmaceutical composition of claim 34 .
42 . A method of treating presbyopia in an individual in need thereof, the method comprising administering to the individual the pharmaceutical composition of claim 34 .Join the waitlist — get patent alerts
Track US2023064711A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.